{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:19:54Z","timestamp":1768015194860,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00380-020-01597-x","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T14:02:51Z","timestamp":1586354571000},"page":"1218-1226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus"],"prefix":"10.1007","volume":"35","author":[{"given":"Shusuke","family":"Fukuoka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Dohi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsushiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keishi","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Omori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"1597_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2840-2-1","volume":"2","author":"C Bauters","year":"2003","unstructured":"Bauters C, Lamblin N, Mc Fadden EP, Van Belle E, Millaire A, de Groote P (2003) Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol 2:1","journal-title":"Cardiovasc Diabetol"},{"key":"1597_CR2","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","volume":"29","author":"MR MacDonald","year":"2008","unstructured":"MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ, CHARM investigators (2008) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29:1377\u20131385","journal-title":"Eur Heart J"},{"key":"1597_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jacc.2003.11.024","volume":"43","author":"I Gustafsson","year":"2004","unstructured":"Gustafsson I, Brendorp B, Seibaek M, Burchardt H, Hidebrandt P, K\u00f8ber L, Torp-Pedersen C, Danish Investigatord of Arrhythmia, and Mortality on Dofetilde Study Group (2004) Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 43:771\u2013777","journal-title":"J Am Coll Cardiol"},{"key":"1597_CR4","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1093\/eurheartj\/ehw110","volume":"37","author":"N Marx","year":"2016","unstructured":"Marx N, McGuire DK (2016) Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J 37:3192\u20133200","journal-title":"Eur Heart J"},{"key":"1597_CR5","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128","journal-title":"N Engl J Med"},{"key":"1597_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw Q, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group (2017) Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med 377:644\u2013657","journal-title":"N Engl J Med"},{"key":"1597_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniler TA, Kruder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, DECLARE-TIMI 58 Investigators (2019) Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N Engl J Med 380:347\u2013357","journal-title":"N Engl J Med"},{"key":"1597_CR8","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","volume":"61","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D'Alessio DA, Fradkin J, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB (2018) Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61:2461\u20132498","journal-title":"Diabetologia"},{"key":"1597_CR9","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J (2013) Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15:853\u2013862","journal-title":"Diabetes Obes Metab"},{"key":"1597_CR10","doi-asserted-by":"publisher","first-page":"F653","DOI":"10.1152\/ajprenal.00143.2018","volume":"315","author":"T Masuda","year":"2018","unstructured":"Masuda T, Watanabe Y, Fukuda K, Watanabe M, Onishi A, Ohara K, Imai T, Koepsell H, Muto S, Vallon V, Nagata D (2018) Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat. Am J Physiol Renal Physiol 315:F653\u2013664","journal-title":"Am J Physiol Renal Physiol"},{"key":"1597_CR11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","volume":"71","author":"M Sano","year":"2018","unstructured":"Sano M (2018) A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol 71:471\u2013476","journal-title":"J Cardiol"},{"key":"1597_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2015.07.072","volume":"201","author":"T Takeuchi","year":"2015","unstructured":"Takeuchi T, Dohi K, Omori T, Moriwaki K, Sato Y, Nakamori S, Fujimoto N, Fujii E, Yamada N, Ito M (2015) Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure. Int J Cardiol 201:1\u20133","journal-title":"Int J Cardiol"},{"key":"1597_CR13","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1253\/circj.CJ-16-0780","volume":"80","author":"G Kimura","year":"2016","unstructured":"Kimura G (2016) Diuretic action of sodium\u2013glucose cotransporter 2 inhibitors and its importance in the management of heart failure. Circ J 80:2277\u20132281","journal-title":"Circ J"},{"key":"1597_CR14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1053\/j.ajkd.2007.09.004","volume":"50","author":"E Imai","year":"2007","unstructured":"Imai E, Horino M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S (2007) Modification of the modification of diet in renal disease (MDRD) study equation for Japan. Am J Kidney Dis 50:927\u2013937","journal-title":"Am J Kidney Dis"},{"key":"1597_CR15","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1253\/circj.CJ-14-0592","volume":"78","author":"K Dohi","year":"2014","unstructured":"Dohi K, Ito M (2014) Novel diuretic strategies for the treatment of heart failure in Japan. Circ J 78:1816\u20131823","journal-title":"Circ J"},{"key":"1597_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129:587\u2013597","journal-title":"Circulation"},{"key":"1597_CR17","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s12325-016-0457-8","volume":"34","author":"H Tanaka","year":"2017","unstructured":"Tanaka H, Takano K, Iijima H, Kubo H, Maruyama N, Hashimoto T, Arakawa K, Togo M, Inagaki N, Kaku K (2017) Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus. Adv Ther 34:436\u2013451","journal-title":"Adv Ther"},{"key":"1597_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jsbmb.2018.08.007","volume":"185","author":"K Itcho","year":"2019","unstructured":"Itcho K, Oki K, Kobuke K, Ohno H, Yoneda M, Hattori N (2019) Angiotensin 1\u20137 suppresses angiotensin II mediated aldosterone production via JAK\/STAT signaling inhibition. J Steroid Biochem Mol Biol 185:137\u2013141","journal-title":"J Steroid Biochem Mol Biol"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-020-01597-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00380-020-01597-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-020-01597-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T23:35:03Z","timestamp":1617838503000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00380-020-01597-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,8]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1597"],"URL":"https:\/\/doi.org\/10.1007\/s00380-020-01597-x","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,8]]},"assertion":[{"value":"30 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M. Ito received departmental research grant support equal to or more than 1,000,000 yen from Otsuka Pharmaceutical Co., Ltd. and Daiichi Sankyo Company Limited in 2018. K.D. lecture fees equal to or more than 500,000 yen from Otsuka Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Company Limited in 2018. All of the other authors have no conflict of interest to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}